Audited Financial Results for the Financial Year ended 31st March, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Asston Pharmaceuticals reported revenue from operations of Rs 2,303.97 Lakhs for FY26, down from Rs 2,546.53 Lakhs in FY25, representing a revenue decline of approximately 9.5%. Net profit for the year stood at Rs 386.52 Lakhs compared to Rs 428.77 Lakhs in the previous year. The company reported negative operating cash flow of Rs 1,017.95 Lakhs, a significant deterioration from Rs 2.53 Lakhs negative in FY25, primarily due to a large increase in trade receivables (Rs 1,201.84 Lakhs). Capital expenditure was substantial at Rs 1,006.26 Lakhs. The auditor issued an unmodified (clean) opinion. The company changed auditors mid-year from M/S Doshi Doshi & Co. to Panchal SK & Associates.
The stock may face pressure due to revenue decline, lower profits, and negative operating cash flow. The significant increase in trade receivables raises concerns about collection efficiency, though the clean audit opinion provides some comfort.